525 related articles for article (PubMed ID: 17402720)
1. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
2. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
[TBL] [Abstract][Full Text] [Related]
3. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
[TBL] [Abstract][Full Text] [Related]
6. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
7. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
8. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
9. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
[TBL] [Abstract][Full Text] [Related]
10. Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.
Reisner E; Arion VB; Eichinger A; Kandler N; Giester G; Pombeiro AJ; Keppler BK
Inorg Chem; 2005 Sep; 44(19):6704-16. PubMed ID: 16156629
[TBL] [Abstract][Full Text] [Related]
11. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
Tan C; Hu S; Liu J; Ji L
Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
[TBL] [Abstract][Full Text] [Related]
13. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
14. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
17. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
[TBL] [Abstract][Full Text] [Related]
19. Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)].
Mura P; Piccioli F; Gabbiani C; Camalli M; Messori L
Inorg Chem; 2005 Jul; 44(14):4897-9. PubMed ID: 15998012
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
